Acorda Therapeutics began in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders.
We have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological disorders.
Everything Acorda does is aimed at improving the lives of millions of people with nervous system disorders and cardiovascular conditions in our local and global communities. In keeping with this mission, Acorda supports neurological and cardiovascular research, education, and patient assistance through grants and sponsorship programs.
We also foster the next generation of scientists through the Acorda Scientific Excellence Award, which recognizes local high school students who are engaged in significant scientific, technological, engineering and mathematical (STEM) research.
We are proud of our contributions in these areas, and we invite you to learn more about our company and our mission on this Facebook page and by visiting www.acorda.com.
We have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological disorders.
Everything Acorda does is aimed at improving the lives of millions of people with nervous system disorders and cardiovascular conditions in our local and global communities. In keeping with this mission, Acorda supports neurological and cardiovascular research, education, and patient assistance through grants and sponsorship programs.
We also foster the next generation of scientists through the Acorda Scientific Excellence Award, which recognizes local high school students who are engaged in significant scientific, technological, engineering and mathematical (STEM) research.
We are proud of our contributions in these areas, and we invite you to learn more about our company and our mission on this Facebook page and by visiting www.acorda.com.
Location: United States, New York, Ardsley
Employees: 201-500
Founded date: 1995
Investors 6
| Date | Name | Website |
| - | PFM Health... | pfmhealths... |
| - | Foresite C... | foresiteca... |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | Omega Fund... | omegafunds... |
| - | Idinvest P... | idinvest.c... |
| - | Fountain H... | fh-partner... |
Mentions in press and media 18
| Date | Title | Description |
| 04.09.2024 | Egret Therapeutics Announces Appointment of Ron Cohen, M.D. to its Board of Directors | Egret Therapeutics, a portfolio company of Turret Capital Management, is a clinical stage biotechnology company focused on function preservation post acute ischemic injury NEW YORK, Sept. 4, 2024 /PRNewswire/ -- Egret Therapeutics today ann... |
| 03.09.2024 | Parkinson’s Disease Drug Market: Trends, Growth, and Segmentation | Share Tweet Share Share Email Parkinson’s disease, a progressive neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia, affects millions of individuals worldwide. As the global population age... |
| 16.03.2024 | Klick Health Launches First AI Social Media Comment Moderator for Life Sciences Industry | KCM+AI provides pharma brands with enhanced handling of pharmacovigilance issues via 24/7 monitoring and automatic comment-holding Klick Health launched Klick Comment Moderator+AI (KCM+AI), the life sciences industry’s first social media co... |
| 15.03.2019 | AstraZeneca vet Jennifer Butler takes charge of Innate Pharma's US biz; C4 raids NIBR | → France’s Innate Pharma has wooed AstraZeneca vet Jennifer Butler to lead the US operations it has set up after acquiring Lumoxiti from the British drugmaker in a rich add-on collaboration deal. Butler’s official ti... |
| 10.01.2018 | FierceBiotech’s #JPM18 live blog: Pricing, Axovant's nightmare, and more | SAN FRANCISCO—Welcome to our third day of rolling J.P. Morgan Healthcare Conference coverage. We're updating throughout the conference, with the latest news at the top. Just scroll down to see all the JPM news we've collected. All update ti... |
| 09.01.2018 | In an era of cures, price-prohibitive drugs are an even harder pill to swallow | San Francisco couldn’t shake the rain on day one of the 2018 J.P. Morgan Healthcare Conference and the life sciences industry couldn’t shake the perennial debate around the price of prescription medicines. The topic quickly hijacked a plena... |
| 08.01.2018 | Term Sheet — Monday, January 8 | GO BIG Good morning, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop BIGGER ICOs: Let’s start with crypto. Some of you cringe when you hear “Initial Coin Offerings,” but it doesn’t appear they’re going awa... |
| 29.08.2017 | FDA derails Acorda's marketing pitch, creating a crisis as flagship drug founders | Acorda just entered a world of hurt. With its patent protection crumbling around its mainstay drug, the FDA has refused to file its application for CVT-301, the rescue program that was designated to take the lead drug’s place... |
| 06.06.2017 | PhIII details boost Acorda as execs rush to FDA with the clock ticking on a time bomb | Ron Cohen, Acorda Shares of Acorda got a boost after the market closed on Monday as investors got a chance to look over the detailed Phase III data for its inhaled levodopa drug CVT-301. And while we already knew that the top-li... |
| 29.03.2017 | Blueprint maps plans for $150M raise; GlaxoSmithKline creates discovery pact with Warp Drive | → Blueprint Medicines $BPMC has filed to raise $150 million in a new stock offering. Most of the new money is being earmarked for upcoming clinical trials of its pipeline drugs. And the company says it will add to the $268 m... |
Show more